News

News Subscription

Sep 24. 2024
Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
Read more
Download
Sep 19. 2024 / Ad hoc announcement
Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding
Read more
Download
Sep 06. 2024 / Ad hoc announcement
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea
Read more
Download
Aug 27. 2024 / Ad hoc announcement
European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea
Read more
Download
Aug 21. 2024
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Read more
Download
Aug 13. 2024 / Ad hoc announcement
Basilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidance
Read more
Download
Jun 20. 2024
Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
Read more
Download
May 16. 2024
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Read more
Download
May 03. 2024
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
Read more
Download
Apr 24. 2024
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
Read more
Download